Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.

Abstract

Steroid refractory acute graft-versus-host-disease of the gut is a serious complication associated with high mortality after allogeneic stem cell transplantation. Treatment options are limited and not predictably effective. We describe the treatment of steroid-refractory acute graft-versus-host-disease with vedolizumab, an antibody directed against integrin α4β7, in 6 patients. All patients responded, and 4 of 6 patients are alive with a median follow-up of 10 months.

• Authors: Yngvar Fløisand, Knut E A Lundin, Vladimir Lazarevic, Jørn Dehli Kristiansen, Liv T N Osnes, Geir E Tjønnfjord, Henrik Mikael Reims, Tobias Gedde-Dahl
• Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (Biol Blood Marrow Transplant) Vol. 23 Issue 1 Pg. 172-175 (01 2017) ISSN: 1523-6536 [Electronic] United States
• PMID: 27777142 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• Gastrointestinal Agents
• Integrins
• Steroids
• integrin alpha4beta7
• vedolizumab

Topics

• Adult
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Female
• Gastrointestinal Agents (therapeutic use)
• Graft vs Host Disease (drug therapy, pathology)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Humans
• Integrins (drug effects)
• Intestinal Diseases (drug therapy)
• Male
• Middle Aged
• Salvage Therapy (methods)
• Steroids (therapeutic use)
• Transplantation, Homologous
• Treatment Outcome